157 related articles for article (PubMed ID: 33268682)
1. [Clinical and Fundamental Approach for Chemotherapy-induced Adverse Effect Attenuation by Oncology Pharmacy Specialists].
Saito Y
Yakugaku Zasshi; 2020; 140(12):1415-1419. PubMed ID: 33268682
[TBL] [Abstract][Full Text] [Related]
2. [Survey of the Efficacy of Long-term and Successive Pharmaceutical Care in Outpatient Chemotherapy by Oncology Pharmacy Specialists].
Saito Y; Harada S; Kobayashi M; Ueda K; Yamazaki K; Kumai M; Miyamoto T; Kasashi K; Yamada T; Komatsu Y; Iseki K
Yakugaku Zasshi; 2018; 138(11):1409-1416. PubMed ID: 30381649
[TBL] [Abstract][Full Text] [Related]
3. Premedication with intravenous magnesium has a protective effect against cisplatin-induced nephrotoxicity.
Saito Y; Kobayashi M; Yamada T; Kasashi K; Honma R; Takeuchi S; Shimizu Y; Kinoshita I; Dosaka-Akita H; Iseki K
Support Care Cancer; 2017 Feb; 25(2):481-487. PubMed ID: 27699503
[TBL] [Abstract][Full Text] [Related]
4. Magnesium co-administration decreases cisplatin-induced nephrotoxicity in the multiple cisplatin administration.
Saito Y; Okamoto K; Kobayashi M; Narumi K; Furugen A; Yamada T; Iseki K
Life Sci; 2017 Nov; 189():18-22. PubMed ID: 28864226
[TBL] [Abstract][Full Text] [Related]
5. PPAR-α Deletion Attenuates Cisplatin Nephrotoxicity by Modulating Renal Organic Transporters MATE-1 and OCT-2.
Freitas-Lima LC; Budu A; Arruda AC; Perilhão MS; Barrera-Chimal J; Araujo RC; Estrela GR
Int J Mol Sci; 2020 Oct; 21(19):. PubMed ID: 33049997
[TBL] [Abstract][Full Text] [Related]
6. L-tetrahydropalmatine attenuates cisplatin-induced nephrotoxicity via selective inhibition of organic cation transporter 2 without impairing its antitumor efficacy.
Li C; Li L; Yi Y; Wang W; Yuan J; Tan F; Fang D; Zeng S; Zhou H; Jiang H
Biochem Pharmacol; 2020 Jul; 177():114021. PubMed ID: 32389634
[TBL] [Abstract][Full Text] [Related]
7. Changes of drug pharmacokinetics mediated by downregulation of kidney organic cation transporters Mate1 and Oct2 in a rat model of hyperuricemia.
Nishizawa K; Yoda N; Morokado F; Komori H; Nakanishi T; Tamai I
PLoS One; 2019; 14(4):e0214862. PubMed ID: 30951542
[TBL] [Abstract][Full Text] [Related]
8. Protective effect of magnesium preloading on cisplatin-induced nephrotoxicity: which dose is more suitable?
Ilhan Y; Onder AH; Ozbay MF; Karakaya G; Sezgin Goksu S; Ozturk B; Coskun HS
Eur Rev Med Pharmacol Sci; 2024 May; 28(9):3403-3413. PubMed ID: 38766796
[TBL] [Abstract][Full Text] [Related]
9. Wedelolactone protects against cisplatin-induced nephrotoxicity in mice via inhibition of organic cation transporter 2.
Wang G; Bi Y; Xiong H; Bo T; Han L; Zhou L; Zhang C; Zhang Y
Hum Exp Toxicol; 2021 Dec; 40(12_suppl):S447-S459. PubMed ID: 34592875
[TBL] [Abstract][Full Text] [Related]
10. Magnesium attenuates cisplatin-induced nephrotoxicity by regulating the expression of renal transporters.
Saito Y; Okamoto K; Kobayashi M; Narumi K; Yamada T; Iseki K
Eur J Pharmacol; 2017 Sep; 811():191-198. PubMed ID: 28529140
[TBL] [Abstract][Full Text] [Related]
11. Organic cation transporter OCT/SLC22A and H(+)/organic cation antiporter MATE/SLC47A are key molecules for nephrotoxicity of platinum agents.
Yonezawa A; Inui K
Biochem Pharmacol; 2011 Mar; 81(5):563-8. PubMed ID: 21144842
[TBL] [Abstract][Full Text] [Related]
12. Enhanced renal accumulation of cisplatin via renal organic cation transporter deteriorates acute kidney injury in hypomagnesemic rats.
Yokoo K; Murakami R; Matsuzaki T; Yoshitome K; Hamada A; Saito H
Clin Exp Nephrol; 2009 Dec; 13(6):578-84. PubMed ID: 19629622
[TBL] [Abstract][Full Text] [Related]
13. Organic cation transporter and multidrug and toxin extrusion 1 co-mediated interaction between metformin and berberine.
Shi R; Xu Z; Xu X; Jin J; Zhao Y; Wang T; Li Y; Ma Y
Eur J Pharm Sci; 2019 Jan; 127():282-290. PubMed ID: 30428337
[TBL] [Abstract][Full Text] [Related]
14. The effects of 2,3-dimercapto-1-propanesulfonic acid (DMPS) and meso-2,3-dimercaptosuccinic acid (DMSA) on the nephrotoxicity in the mouse during repeated cisplatin (CDDP) treatments.
Yajima Y; Kawaguchi M; Yoshikawa M; Okubo M; Tsukagoshi E; Sato K; Katakura A
J Pharmacol Sci; 2017 Jun; 134(2):108-115. PubMed ID: 28648300
[TBL] [Abstract][Full Text] [Related]
15. A pilot study to assess the pharmacy impact of implementing a chemotherapy-induced nausea or vomiting collaborative disease therapy management in the outpatient oncology clinics.
Jackson K; Letton C; Maldonado A; Bodiford A; Sion A; Hartwell R; Graham A; Bondarenka C; Uber L
J Oncol Pharm Pract; 2019 Jun; 25(4):847-854. PubMed ID: 29587608
[TBL] [Abstract][Full Text] [Related]
16. Protective effect of concomitant administration of imatinib on cisplatin-induced nephrotoxicity focusing on renal organic cation transporter OCT2.
Tanihara Y; Masuda S; Katsura T; Inui K
Biochem Pharmacol; 2009 Nov; 78(9):1263-71. PubMed ID: 19540211
[TBL] [Abstract][Full Text] [Related]
17. Absence of effect of SLC22A2 genotype on cisplatin-induced nephrotoxicity in oesophageal cancer patients receiving cisplatin and 5-fluorouracil: report of results discordant with those of earlier studies.
Hinai Y; Motoyama S; Niioka T; Miura M
J Clin Pharm Ther; 2013 Dec; 38(6):498-503. PubMed ID: 24102360
[TBL] [Abstract][Full Text] [Related]
18. Pharmaceutical Care Contributes to the Advanced Management of Patients Receiving Immune Checkpoint Inhibitors.
Saito Y; Uchiyama K; Sakamoto T; Yamazaki K; Kubota K; Takekuma Y; Komatsu Y; Sugawara M
Biol Pharm Bull; 2020; 43(12):1969-1974. PubMed ID: 33268718
[TBL] [Abstract][Full Text] [Related]
19. Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity.
Yokoo S; Yonezawa A; Masuda S; Fukatsu A; Katsura T; Inui K
Biochem Pharmacol; 2007 Aug; 74(3):477-87. PubMed ID: 17582384
[TBL] [Abstract][Full Text] [Related]
20. [Oncology pharmacy specialists in oncology].
Ikesue H; Oishi R
Gan To Kagaku Ryoho; 2008 Apr; 35(4):578-82. PubMed ID: 18408426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
